Compare Gilead Sciences, Inc. (GILD) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Spotify Technology — how do they compare? Gilead Sciences, Inc. trades at $149 (market cap $182.40B), while Spotify Technology trades at $537.6 (market cap $108.22B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Spotify Technology pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Spotify Technology for 111 Days on average.
| GILD | SPOT | |
|---|---|---|
Market Cap | $182.40B | $108.22B |
Volume | 4,469,821 | 1,655,796 |
Sector | Health | Media |
52-Week High | $155.80 | $692.04 |
52-Week Low | $116.74 | $412.75 |
Typical Hold Time | 111 Days | 111 Days |
Enterprise Value | $205.46B | $98.23B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Spotify (SPOT) trades at $512.92, up 5.08% with strong bullish technical signals from moving averages. The company demonstrates robust fundamental momentum with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability with net income reaching $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst consensus remains overwhelmingly positive with 62% buy ratings and a $608.18 price target representing 19% upside potential.
The outlook remains favorable with projected 2026 revenue of $18.1B and net income of $3.3B, though risks include competitive pressures in streaming and recent stock volatility. Key catalysts include Q3 2026 earnings release on October 22, 2026, and continued gross margin expansion from 32.8% currently. Institutional sentiment appears constructive given the strong buy-side analyst coverage and improving cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
